DE-RISKING
Preclinical EEG: A Key Tool in De-risking
De-risking in preclinical EEG involves identifying and mitigating potential risks of drug candidates early in the development process, focusing on their effects on the Central Nervous System (CNS). This approach improves safety and efficacy before clinical trials, reducing the high attrition rates in drug development. EEG assessments are used at early preclinical stage to characterize a drug’s potential to induce seizures, which is a critical safety concern.
At SynapCell, we primarily focus on de-risking in Epilepsy Absence.
Absence Epilepsy: How We De-Risk a Compound Using Preclinical EEG and the GAERS Rat Model
Absence Epilepsy is a specific type of Epilepsy causing non-convulsive seizures with behavioral arrest and generalized non-motor seizures, while patients’ brain activity shows bilateral, synchronous spike-and-wave discharges (SWD). De-risking involves assessing a molecule’s potential to aggravate Absence Epilepsy seizures, due to:
- Antiseizure medications: Absence seizures can be controlled or worsened by medications for other types of Epilepsy. It’s essential to determine if a molecule effective for focal seizures for example can worsen absence seizures.
- Other treatments: Patients with both Absence Epilepsy and other conditions (such as psychiatric disorders) may take treatments (e.g., antipsychotics like haloperidol) that could worsen absence seizures. De-risking helps assess this risk.
At SynapCell, we specialize in de-risking compounds using the GAERS rat model – a highly translational, gold-standard model for evaluating compounds in Absence Epilepsy – and its SWD EEG biomarker for the early detection and measurement of a compound’s potential to aggravate absence seizures, including seizure number, duration, dose-response, and chronic effects.
Powered by Cue®, SynapCell's Predictive In Vivo EEG Platform
SynapCell’s models and their associated EEG biomarkers are processed on Cue®, our innovative translational in vivo EEG platform, which is designed to predict the in-human efficacy of your drug candidates during the preclinical step. Cue® is the result of decades of R&D, combining SynapCell’s know-how, expertise and scientific excellence in the fields of brain surgery and EEG signal recording, processing, and analysis.
Using Cue®, we transform preclinical data into actionable insights, offering end-to-end support for informed decision-making in CNS drug discovery.
Let's Talk About Your Research Project!
More than a CRO, a team of collaborators – we are your dream neuroscience team specialized in preclinical EEG! We don’t just produce data, we are your partners from conceptualization to conclusion. We translate raw EEG data into meaningful, clinically-relevant endpoints, delivering clear insights to allow data-based decision-making. Choose SynapCell, a leading preclinical CNS-specialized CRO for cutting-edge EEG expertise combined with an irresistible touch of fun.
News & Events